From osteoarthritis to rheumatoid arthritis: re-exploring the molecular pathways and therapeutic potential of diacerein

Abstract

Diacerein, an anthraquinone derivative, is emerging as a promising disease-modifying agent in rheumatoid arthritis (RA), because of its potent anti-inflammatory and chondroprotective actions. Unlike nonsteroidal anti-inflammatory drugs, which primarily inhibit cyclooxygenase enzymes, diacerein suppresses interleukin-1β, a central mediator of synovial inflammation and cartilage degradation. It also modulates tumor necrosis factor-alpha and matrix metalloproteinases, thereby alleviating pain, decreasing inflammation, and preserving joint structure. This review of clinical and preclinical studies highlights the therapeutic potential of diacerein in RA management, focusing on its molecular mechanisms, clinical outcomes, and combination strategies with disease-modifying antirheumatic drugs (DMARDs) or biologics. Recent advances in drug delivery, including nanoparticle-based and sustained-release formulations, have further enhanced its bioavailability and efficacy. Diacerein effectively decreases joint swelling and stiffness, while demonstrating a superior gastrointestinal safety profile to nonsteroidal anti-inflammatory drugs. However, its slow onset of action and moderate efficacy as a monotherapy limit its standalone use. Combination therapy with DMARDs or biologics appears to potentiate its therapeutic benefits. Overall, diacerein is a valuable adjunctive agent in RA treatment. Further studies are warranted to optimize dosing regimens and delivery systems to improve clinical outcomes.

Keywords

Diacerein / Rheumatoid Arthritis / Molecular Pathways / Disease-Modifying Antirheumatic Drugs (DMARDs) / Chondroprotection / Anti-inflammatory

References

[1] Sailaja AK: An Overall Review on Rheumatoid Arthritis. Journal of Current Pharma Research 2014, 4: 1138-1143.

[2] Shrivastava AK, Pandey A: Inflammation and Rheumatoid Arthritis. Journal of Physiology and Biochemistry 2013, 69: 335-347.

[3] Arleevskaya M, Takha E, Petrov S, Kazarian G, Renaudineau Y, Brooks W, et al.: Interplay of Environmental, Individual and Genetic Factors in Rheumatoid Arthritis Provocation. International Journal of Molecular Sciences 2022, 23: 8140.

[4] Wysocki T, Olesińska M, Paradowska-Gorycka A: Current Understanding of An Emerging Role of HLA-DRB1 Gene in Rheumatoid Arthritis-From Research to Clinical Practice. Cells 2020, 9: 1127.

[5] Noss EH, Brenner MB: The Role and Therapeutic Implications of Fibroblast-like Synoviocytes in Inflammation and Cartilage Erosion in Rheumatoid Arthritis. Immunological Reviews 2008, 223: 252-270.

[6] van Delft MAM, Huizinga TWJ: An Overview of Autoantibodies in Rheumatoid Arthritis. Journal of Autoimmunity 2020, 110: 102392.

[7] van Laar M, Pergolizzi JV Jr, Mellinghoff HU, Merchante IM, Nalamachu S, O’Brien J, et al.: Pain Treatment in Arthritis-related Pain: Beyond NSAIDs. The Open Rheumatology Journal 2012, 6: 320-330.

[8] Crofford LJ: Use of NSAIDs in Treating Patients with Arthritis. Arthritis Research & Therapy 2013, 15: S2.

[9] Dar E, Abbas M, Nazir S, Abbas M: Novel Management, Cure and Complications-Control of Rheumatoid Arthritis with Traditional and Modern Remedies (A Review). Pharmaceutical Chemistry Journal 2024, 58: 1020-1028.

[10] Akram M, Daniyal M, Sultana S, Owais A, Akhtar N, Zahid R, et al.: Traditional and Modern Management Strategies for Rheumatoid Arthritis. Clinica Chimica Acta 2021, 512: 142-155.

[11] Li P, Zheng Y, Chen X: Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics. Frontiers in Pharmacology 2017, 8: 460.

[12] Croft M, Siegel RM: Beyond TNF: TNF Superfamily Cytokines as Targets for the Treatment of Rheumatic Diseases. Nature Reviews. Rheumatology 2017, 13: 217-233.

[13] Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al.: Risk of Serious Infection in Biological Treatment of Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Lancet 2015, 386: 258-265.

[14] Ben Mrid R, Bouchmaa N, Ainani H, El Fatimy R, Malka G, Mazini L: Anti-rheumatoid Drugs Advancements: New Insights into the Molecular Treatment of Rheumatoid Arthritis. Biomedicine & Pharmacotherapy 2022, 151: 113126.

[15] Sarkar PK, Hossain N, Nahid M, Alam J: Disease Modifying Anti-rheumatic Drugs (DMARDs). Bangladesh Journal of Child Health 2018, 42: 79-85.

[16] Kuczynski EA, Sargent DJ, Grothey A, Kerbel RS: Drug Rechallenge and Treatment beyond Progression-Implications for Drug Resistance. Nature Reviews. Clinical Oncology 2013, 10: 571-587.

[17] Singh JA, Hossain A, Tanjong Ghogomu E, Kotb A, Christensen R, Mudano AS, et al.: Biologics or Tofacitinib for Rheumatoid Arthritis in Incomplete Responders to Methotrexate or Other Traditional Disease-modifying Anti-rheumatic Drugs: A Systematic Review and Network Meta-analysis. The Cochrane Database of Systematic Reviews 2016, 2016: CD012183.

[18] Aldea M, Andre F, Marabelle A, Dogan S, Barlesi F, Soria JC: Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies. Cancer Discovery 2021, 11: 874-899.

[19] Dagogo-Jack I, Shaw AT: Tumour Heterogeneity and Resistance to Cancer Therapies. Nature Reviews. Clinical Oncology 2018, 15: 81-94.

[20] Zampeli E, Vlachoyiannopoulos PG, Tzioufas AG: Treatment of Rheumatoid Arthritis: Unraveling the Conundrum. Journal of Autoimmunity 2015, 65: 1-18.

[21] El-Aziz Fathy EA, Abdel-Gaber SA, Gaber Ibrahim MF, Thabet K, Waz S: Downregulation of IL-1β/p38 Mitogen Activated Protein Kinase Pathway by Diacerein Protects against Kidney Ischemia/reperfusion Injury in Rats. Cytokine 2024, 176: 156511.

[22] Ahmed E, Mostafa B, Maged A, Shaker O: Evaluation of the Effect of Diacerein on IL-1β and Osteocalcin levels in GCF of Chronic Periodontitis Patients: A non-randomized controlled clinical trial. Journal of International Dental and Medical Research 2016, 9: 98.

[23] Boileau C, Tat SK, Pelletier JP, Cheng S, Martel-Pelletier J: Diacerein Inhibits the Synthesis of Resorptive Enzymes and Reduces Osteoclastic Differentiation/Survival in Osteoarthritic Subchondral Bone: A Possible Mechanism for a Protective Effect against Subchondral Bone Remodelling. Arthritis Research & Therapy 2008, 10: R71.

[24] Roy T, Chowdhury RR, Chakraborty P, Dey S, Chatterjee TK: Pharmacological Applications of Diacerein: A Review. International Journal of Health Sciences 2022, 6: 11738-11749.

[25] Zhao R, Zhou H, Su SB: A Critical Role for Interleukin-1β in the Progression of Autoimmune Diseases. International Immunopharmacology 2013, 17: 658-669.

[26] Molina-Lopez C, Hurtado-Navarro L, O’Neill LAJ, Pelegrin P: 4-Octyl Itaconate Reduces Human NLRP3 Inflammasome Constitutive Activation with the Cryopyrin-associated Periodic Syndrome p.R262W, p.D305N and p.T350M Variants. Cellular and Molecular Life Sciences 2025, 82: 209.

[27] Lukens JR, Kanneganti TD: Beyond Canonical Inflammasomes: Emerging Pathways in IL-1-mediated Autoinflammatory Disease. Seminars in Immunopathology 2014, 36: 595-609.

[28] Peace CG, O’Neill LA: The Role of Itaconate in Host Defense and Inflammation. The Journal of Clinical Investigation 2022, 132: e148548.

[29] Xu L, Cai J, Li C, Yang M, Duan T, Zhao Q, et al.: 4-Octyl Itaconate Attenuates LPS-induced Acute Kidney Injury by Activating Nrf2 and Inhibiting STAT3 Signaling. Molecular Medicine (Cambridge, Mass.) 2023, 29: 58.

[30] Swaroop AK, Negi P, Kar A, Mariappan E, Natarajan J, Namboori PKK, et al.: Navigating IL-6: From Molecular Mechanisms to Therapeutic Breakthroughs. Cytokine & Growth Factor Reviews 2024, 76: 48-76.

[31] Amaral A, Fernandes C, Szóstek-Mioduchowska A, Lukasik K, Rebordão MR, Pinto-Bravo P, et al.: The Inhibitory Effect of Noscapine on the In Vitro Cathepsin G-Induced Collagen Expression in Equine Endometrium. Life (Basel) 2021, 11: 1107.

[32] Alivernini S, Firestein GS, McInnes IB: The Pathogenesis of Rheumatoid Arthritis. Immunity 2022, 55: 2255-2270.

[33] Pavelka K, Bruyère O, Cooper C, Kanis JA, Leeb BF, Maheu E, et al.: Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. Drugs & Aging 2016, 33: 75-85.

[34] Martel-Pelletier J, Pelletier JP: Effects of Diacerein at the Molecular Level in the Osteoarthritis Disease Process. Therapeutic Advances in Musculoskeletal Disease 2010, 2: 95-104.

[35] Li GM, Chen JR, Zhang HQ, Cao XY, Sun C, Peng F, et al.: Update on Pharmacological Activities, Security, and Pharmacokinetics of Rhein. Evidence-based Complementary and Alternative Medicine 2021, 2021: 4582412.

[36] Huang M, Zong SL, Zhang QY: The Effect of Food Intake on the pk of Rhein Released from Diacerein. Brazilian Journal of Pharmaceutical Sciences 2020, 56.

[37] Oo WM, Little C, Duong V, Hunter DJ: The Development of Disease-Modifying Therapies for Osteoarthritis (DMOADs): The Evidence to Date. Drug Design, Development and Therapy 2021, 15: 2921-2945.

[38] Karnam S, Donthi MR, Jindal AB, Paul AT: Recent Innovations in Topical Delivery for Management of Rheumatoid Arthritis: A Focus on Combination Drug Delivery. Drug Discov Today 2024, 29: 104071.

[39] Li G, Zhang Z, Ye Y, Li H, Luo H, Tang K, et al.: Efficacy, Residual Effectiveness and Safety of Diacerein in the Treatment of Knee Osteoarthritis: A Meta-analysis of Randomized Placebo-controlled Trials. Medicine (Baltimore) 2022, 101: e31700.

[40] Pflugbeil S, Böckl K, Pongratz R, Leitner M, Graninger W, Ortner A: Drug Interactions in the Treatment of Rheumatoid Arthritis and Psoriatic Arthritis. Rheumatology International 2020, 40: 511-521.

[41] Cardoso CRL, Leite NC, Carlos FO, Loureiro AA, Viegas BB, Salles GF: Efficacy and Safety of Diacerein in Patients With Inadequately Controlled Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care 2017, 40: 1356-1363.

[42] Ding Q, Hu W, Wang R, Yang Q, Zhu M, Li M, et al.: Signaling Pathways in Rheumatoid Arthritis: Implications for Targeted Therapy. Signal Transduction and Targeted Therapy 2023, 8: 68.

[43] Zeng F, Wang K, Duan H, Xu XT, Kuang GY, Lu M: Diacerein Versus Non-steroidal Anti-inflammatory Drugs in the Treatment of Knee Osteoarthritis: A Meta-analysis. Journal of Orthopaedic Surgery and Research 2023, 18: 308.

[44] Ciobanu DA, Poenariu IS, Crînguș LI, Vreju FA, Turcu-Stiolica A, Tica AA, et al.: JAK/STAT Pathway in Pathology of Rheumatoid Arthritis (Review). Experimental and Therapeutic Medicine 2020, 20: 3498-3503.

[45] Ali GF, Hassanein EHM, Abdel-Reheim MA, Arafa EA, Mohamed WR: Involvement of IL-6/JAK/STAT3/SOCS3, SIRT1, and Cytoglobin Signaling in Diacerein Protective Effect against Intestinal Injury Induced by Methotrexate. Journal of Biochemical and Molecular Toxicology 2025, 39: e70339.

[46] Hu X, Li J, Fu M, Zhao X, Wang W: The JAK/STAT Signaling Pathway: From Bench to Clinic. Signal Transduction and Targeted Therapy 2021, 6: 402.

[47] Peng X, Chen X, Zhang Y, Tian Z, Wang M, Chen Z: Advances in the Pathology and Treatment of Osteoarthritis. Journal of Advanced Research 2025, 78: 257-283.

[48] Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X, et al.: Wnt/β-catenin Signalling: Function, Biological Mechanisms, and Therapeutic Opportunities. Signal Transduction and Targeted Therapy 2022, 7: 3.

[49] Eisa NH, Said E, Khodir AE, Sabry D, Ebrahim HA, Elsherbini DMA, et al.: Effect of Diacerein on HOTAIR/IL-6/STAT3, Wnt/β-Catenin and TLR-4/NF-κB/TNF-α Axes in Colon Carcinogenesis. Environmental Toxicology and Pharmacology 2022, 95: 103943.

[50] Xue C, Chu Q, Shi Q, Zeng Y, Lu J, Li L: Wnt Signaling Pathways in Biology and Disease: Mechanisms and Therapeutic Advances. Signal Transduction and Targeted Therapy 2025, 10: 106.

[51] Rodriguez-Trillo A, Mosquera N, Pena C, Rivas-Tobío F, Mera-Varela A, Gonzalez A, et al.: Non-Canonical WNT5A Signaling Through RYK Contributes to Aggressive Phenotype of the Rheumatoid Fibroblast-Like Synoviocytes. Frontiers in Immunology 2020, 11: 555245.

[52] Yue S, Fan J, Xie D, Cao C, Wang Z, Huang J, et al.: Unveiling the Therapeutic Potential: Targeting Fibroblast-Like Synoviocytes in Rheumatoid Arthritis. Expert Reviews in Molecular Medicine 2025, 27: e18.

[53] Di Bartolomeo L, Vaccaro F, Irrera N, Borgia F, Li Pomi F, Squadrito F, et al.: Wnt Signaling Pathways: From Inflammation to Non-melanoma Skin Cancers. International Journal of Molecular Sciences 2023, 24: 1575.

[54] Almezgagi M, Zhang Y, Hezam K, Shamsan E, Gamah M, Al-Shaebi F, et al.: Diacerein: Recent Insight into Pharmacological Activities and Molecular Pathways. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 2020, 131: 110594.

[55] Chen X, Zhu X, Dong J, Chen F, Gao Q, Zhang L, et al.: Reversal of Epigenetic Peroxisome Proliferator-Activated Receptor-γ Suppression by Diacerein Alleviates Oxidative Stress and Osteoarthritis in Mice. Antioxidants & Redox Signaling 2022, 37: 40-53.

[56] Fang T, Zhou X, Jin M, Nie J, Li X: Molecular Mechanisms of Mechanical Load-induced Osteoarthritis. International Orthopaedics 2021, 45: 1125-1136.

[57] Martorell M, Castro N, Victoriano M, Capó X, Tejada S, Vitalini S, et al.: An Update of Anthraquinone Derivatives Emodin, Diacerein, and Catenarin in Diabetes. Evidence-based Complementary and Alternative Medicine 2021, 2021: 3313419.

[58] Gayathri CR, Samuel V, Senthilnathan A, Nirmala P: Compliance and Tolerability Evaluation of Diacerein Versus S-adenosyl Methionine in Osteoarthritis Patients. International Archives of Integrated Medicine 2017, 4: 6-13.

[59] Steinecker-Frohnwieser B, Weigl L, Kullich W, Lohberger B: The Disease Modifying Osteoarthritis Drug Diacerein is Able to Antagonize Pro Inflammatory State of Chondrocytes Under Mild Mechanical Stimuli. Osteoarthritis and Cartilage 2014, 22: 1044-1052.

[60] Steinecker-Frohnwieser B, Kaltenegger H, Weigl L, Mann A, Kullich W, Leithner A, et al.: Pharmacological Treatment with Diacerein Combined with Mechanical Stimulation Affects the Expression of Growth Factors in Human Chondrocytes. Biochemistry and Biophysics Reports 2017, 11: 154-160.

[61] McInnes IB, Schett G: The Pathogenesis of Rheumatoid Arthritis. New England Journal of Medicine 2011, 365: 2205-2219.

[62] Raphael I, Nalawade S, Eagar TN, Forsthuber TG: T Cell Subsets and Their Signature Cytokines in Autoimmune and Inflammatory Diseases. Cytokine 2015, 74: 5-17.

[63] Hampe CS: B Cell in Autoimmune Diseases. Scientifica (Cairo) 2012, 2012: 215308.

[64] Huang J, Fu X, Chen X, Li Z, Huang Y, Liang C: Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis. Frontiers in Immunology 2021, 12: 686155.

[65] Tabeian H, Betti BF, Dos Santos Cirqueira C, de Vries TJ, Lobbezoo F, Ter Linde AV, et al.: IL-1β Damages Fibrocartilage and Upregulates MMP-13 Expression in Fibrochondrocytes in the Condyle of the Temporomandibular Joint. International Journal of Molecular Sciences 2019, 20: 2260.

[66] Li L, Liu H, Shi W, Liu H, Yang J, Xu D, et al.: Insights into the Action Mechanisms of Traditional Chinese Medicine in Osteoarthritis. Evidence-based Complementary and Alternative Medicine 2017, 2017: 5190986.

[67] Arnold KM, Weaver SR, Zars EL, Tschumperlin DJ, Westendorf JJ: Inhibition of Phlpp1 Preserves the Mechanical Integrity of Articular Cartilage in a Murine Model of Post-traumatic Osteoarthritis. Osteoarthritis and Cartilage 2024, 32: 680-689.

[68] Liu S, Deng Z, Chen K, Jian S, Zhou F, Yang Y, et al.: Cartilage Tissue Engineering: From Proinflammatory and Anti-inflammatory Cytokines to Osteoarthritis Treatments (Review). Molecular Medicine Reports 2022, 25: 99.

[69] Li Z, Meng D, Li G, Xu J, Tian K, Li Y: Celecoxib Combined with Diacerein Effectively Alleviates Osteoarthritis in Rats via Regulating JNK and p38MAPK Signaling Pathways. Inflammation 2015, 38: 1563-1572.

[70] Sharma AR, Jagga S, Lee SS, Nam JS: Interplay between Cartilage and Subchondral Bone Contributing to Pathogenesis of Osteoarthritis. International Journal of Molecular Sciences 2013, 14: 19805-19830.

[71] Lohberger B, Kaltenegger H, Weigl L, Mann A, Kullich W, Stuendl N, et al.: Mechanical Exposure and Diacerein Treatment Modulates Integrin-FAK-MAPKs Mechanotransduction in Human Osteoarthritis Chondrocytes. Cellular Signalling 2019, 56: 23-30.

[72] Jung JH, Kim SE, Kim HJ, Park K, Song GG, Choi SJ: A Comparative Pilot Study of Oral Diacerein and Locally Treated Diacerein-loaded Nanoparticles in a Model of Osteoarthritis. International Journal of Pharmaceutics 2020, 581: 119249.

[73] Abdel-Aziz MA, Ahmed HMS, El-Nekeety AA, Sharaf HA, Abdel-Aziem SH, Abdel-Wahhab MA: Biosynthesis of Gold Nanoparticles for the Treatment of Osteoarthritis Alone or in Combination with Diacerein^® in a Rat Model . Inflammopharmacology 2021, 29: 705-719.

[74] Pelletier JP, Raynauld JP, Dorais M, Bessette L, Dokoupilova E, Morin F, et al.: An International, Multicentre, Double-blind, Randomized Study (DISSCO): Effect of Diacerein vs Celecoxib on Symptoms in Knee Osteoarthritis. Rheumatology (Oxford) 2020, 59: 3858-3868.

[75] Cai G, Jones G, Cicuttini FM, Wluka AE, Wang Y, Hill C, et al.: Study Protocol for a Randomised Controlled Trial of Diacerein Versus Placebo to Treat Knee Osteoarthritis with Effusion-synovitis (DICKENS). Trials 2022, 23: 768.

[76] Dusad A, Pedro S, Mikuls TR, Hartman CW, Garvin KL, O’Dell JR, et al.: Impact of Total Knee Arthroplasty as Assessed Using Patient-Reported Pain and Health-Related Quality of Life Indices: Rheumatoid Arthritis Versus Osteoarthritis. Arthritis & Rheumatology (Hoboken, N.J.) 2015, 67: 2503-2511.

[77] Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J: Rheumatoid Arthritis: Pathological Mechanisms and Modern Pharmacologic Therapies. Bone Research 2018, 6: 15.

[78] Elshal M, Abdelmageed ME: Diacerein Counteracts Acetaminophen-induced Hepatotoxicity in Mice via Targeting NLRP3/caspase-1/IL-1β and IL-4/MCP-1 Signaling Pathways. Archives of Pharmacal Research 2022, 45: 142-158.

[79] Louthrenoo W, Nilganuwong S, Nanagara R, Siripaitoon B, Collaud Basset S: Diacerein for the Treatment of Rheumatoid Arthritis in Patients with Inadequate Response to Methotrexate: A Pilot Randomized, Double-blind, Placebo-controlled Add-on trial. Clinical Rheumatology 2019, 38: 2461-2471.

[80] Louthrenoo W, Nilganuwong S, Nanagara R, Siripaitoon B: THU0207 Diacerein in Combination with Methotrexate versus Methotrexate Alone in The Treatment of Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases 2016, 75: 262.

[81] Bartels EM, Bliddal H, Schøndorff PK, Altman RD, Zhang W, Christensen R: Symptomatic Efficacy and Safety of Diacerein in the Treatment of Osteoarthritis: A Meta-analysis of Randomized Placebo-controlled Trials. Osteoarthritis and Cartilage 2010, 18: 289-296.

[82] Jain A, Singh SK, Singh Y, Singh S: Development of Lipid Nanoparticles of Diacerein, an Antiosteoarthritic Drug for Enhancement in Bioavailability and Reduction in Its Side Effects. Journal of Biomedical Nanotechnology 2013, 9: 891-900.

[83] Kaur D, Kaur J, Kamal SS: Diacerein, Its Beneficial Impact on Chondrocytes and Notable New Clinical Applications. Brazilian Journal of Pharmaceutical Sciences 2019, 54: e17534.

[84] Albrecht K, Müller-Ladner U: Side Effects and Management of Side Effects of Methotrexate in Rheumatoid Arthritis. Clinical and Experimental Rheumatology 2010, 28: S95-S101.

[85] Wang W, Zhou H, Liu L: Side Effects of Methotrexate Therapy for Rheumatoid Arthritis: A Systematic Review. European Journal of Medicinal Chemistry 2018, 158: 502-516.

[86] Yazici Y, Erkan D, Harrison MJ, Nikolov NP, Paget SA: Methotrexate Use in Rheumatoid Arthritis is Associated with Few Clinically Significant Liver Function Test Abnormalities. Clinical and Experimental Rheumatology 2005, 23: 517-520.

[87] Thakur S, Riyaz B, Patil A, Kaur A, Kapoor B, Mishra V: Novel Drug Delivery Systems for NSAIDs in Management of Rheumatoid Arthritis: An Overview. Biomedicine & Pharmacotherapy 2018, 106: 1011-1023.

[88] Möller B, Pruijm M, Adler S, Scherer A, Villiger PM, Finckh A: Chronic NSAID Use and Long-term Decline of Renal Function in a Prospective Rheumatoid Arthritis Cohort Study. Annals of the Rheumatic Diseases 2015, 74: 718-723.

[89] Marcum ZA, Hanlon JT: Recognizing the Risks of Chronic Nonsteroidal Anti-Inflammatory Drug Use in Older Adults. The Annals of Long-term Care 2010, 18: 24-27.

[90] Scott DL: Biologics-based Therapy for the Treatment of Rheumatoid Arthritis. Clinical Pharmacology and Therapeutics 2012, 91: 30-43.

[91] Rubbert-Roth A, Szabó MZ, Kedves M, Nagy G, Atzeni F, Sarzi-Puttini P: Failure of Anti-TNF Treatment in Patients with Rheumatoid Arthritis: The Pros and Cons of the Early Use of Alternative Biological Agents. Autoimmunity Reviews 2019, 18: 102398.

[92] Rubbert-Roth A: Assessing the Safety of Biologic Agents in Patients with Rheumatoid Arthritis. Rheumatology (Oxford) 2012, 51: v38-v47.

[93] Naseri M, Ghobakhlou S, Heidarizade N, Akbari ME, Lotfabadi A, Sadegh Malvajerd S, et al.: Advances in Drug Delivery Science for Diacerein: Strategies to Enhance Solubility, Bioavailability, and Pharmacokinetic Performance. Pharmaceutics 2025, 17: 1539.

[94] Javed I, Hussain SZ, Shahzad A, Khan JM, Ur-Rehman H, Rehman M, et al.: Lecithin-gold Hybrid Nanocarriers as Efficient and pH Selective Vehicles for Oral Delivery of Diacerein-In-vitro and in-vivo Study. Colloids and Surfaces B Biointerfaces 2016, 141: 1-9.

[95] El-Laithy HM, Basalious EB, El-Hoseiny BM, Adel MM: Novel Self-nanoemulsifying Self-nanosuspension (SNESNS) for Enhancing Oral Bioavailability of Diacerein: Simultaneous Portal Blood Absorption and Lymphatic Delivery. International Journal of Pharmaceutics 2015, 490: 146-154.

[96] Paulino DSM, Mendes MCS, Camargo JA, Brambilla SR, Wood Dos Santos T, Ribeiro ML, et al.: Diacerein Treatment Prevents Colitis-associated Cancer in Mice. World Journal of Clinical Oncology 2020, 11: 732-746.

[97] Shams S, Martinez JM, Dawson JRD, Flores J, Gabriel M, Garcia G, et al.: The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions. Frontiers in Pharmacology 2021, 12: 680043.

[98] Ali Z, Sharma S, Ain S, Ain Q, Kumar B: Recent Advances in Osteoarthritis: Pathophysiology, Diagnosis, and Therapeutic Strategies. Cuestiones de Fisioterapia 2025, 54: 787-811.

[99] Chueakula N, Jaikumkao K, Arjinajarn P, Pongchaidecha A, Chatsudthipong V, Chattipakorn N, et al.: Diacerein Alleviates Kidney Injury through Attenuating Inflammation and Oxidative Stress in Obese Insulin-resistant Rats. Free Radical Biology & Medicine 2018, 115: 146-155.